Luteolin peracetate and gossypolone inhibit immune complex-mediated neutrophil activation
epidermolysis bullosa acquisita
gossypolone
luteolin peracetate
natural products
neutrophils
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
03
2023
accepted:
15
08
2023
medline:
19
9
2023
pubmed:
18
9
2023
entrez:
18
9
2023
Statut:
epublish
Résumé
Natural products have been shown to an important source of therapeutics for human disease. In this study, we aimed to identify natural compounds as potential therapeutics for epidermolysis bullosa acquisita (EBA), an autoimmune disease caused by autoantibodies to type VII collagen (COL7). Utilizing an Three natural compounds, namely luteolin peracetate, gossypol, and gossypolone were capable in inhibiting the IC-induced neutrophil adhesion and oxygen burst In summary, this study demonstrates that luteolin peracetate and gossypolone are potential therapeutics for experimental EBA, which deserves further investigation.
Identifiants
pubmed: 37720234
doi: 10.3389/fimmu.2023.1196116
pmc: PMC10503437
doi:
Substances chimiques
gossypolone
4547-72-2
Gossypol
KAV15B369O
Antigen-Antibody Complex
0
Luteolin
KUX1ZNC9J2
Biological Products
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1196116Informations de copyright
Copyright © 2023 Yang, Yin, Yue, Bieber, Riemekasten, Ludwig, Petersen and Yu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Methods Mol Biol. 2013;1046:295-306
pubmed: 23868595
Acta Pharmacol Sin. 2009 May;30(5):597-604
pubmed: 19363517
J Agric Food Chem. 2008 Jun 25;56(12):4393-8
pubmed: 18517219
J Invest Dermatol. 2005 May;124(5):958-64
pubmed: 15854036
Acta Derm Venereol. 2011 May;91(3):307-12
pubmed: 21394418
Lancet. 2013 Jan 26;381(9863):320-32
pubmed: 23237497
Electrophoresis. 1997 Jan;18(1):142-9
pubmed: 9059836
J Nutr Sci. 2016 Dec 29;5:e47
pubmed: 28620474
J Immunol. 2006 Sep 1;177(5):3461-8
pubmed: 16920988
J Cell Biol. 1987 Mar;104(3):611-21
pubmed: 3818794
Blood. 2004 Mar 1;103(5):1602-10
pubmed: 14592823
Viruses. 2020 Feb 06;12(2):
pubmed: 32041232
J Invest Dermatol. 2010 Dec;130(12):2841-4
pubmed: 20720565
J Pathol. 2012 Sep;228(1):1-7
pubmed: 22692770
Arch Dermatol. 1971 Jan;103(1):1-10
pubmed: 4321800
PLoS One. 2012;7(2):e31066
pubmed: 22328927
Curr Med Chem. 2019;26(10):1849-1873
pubmed: 28545375
Agents Actions. 1990 Jun;30(3-4):393-402
pubmed: 1974733
Bioorg Med Chem. 2005 Jul 1;13(13):4228-37
pubmed: 15878283
Brain Res Bull. 2015 Oct;119(Pt A):1-11
pubmed: 26361743
J Clin Invest. 2005 Apr;115(4):870-8
pubmed: 15841176
FEBS Lett. 1998 Nov 6;438(3):220-4
pubmed: 9827549
J Dermatol Sci. 2021 Dec;104(3):154-163
pubmed: 34916040
Am J Pathol. 2002 Jul;161(1):301-11
pubmed: 12107115
Gene. 1992 Jun 15;115(1-2):151-7
pubmed: 1612430
Int Immunopharmacol. 2013 Feb;15(2):442-9
pubmed: 23352443
J Pathol. 2007 May;212(1):56-65
pubmed: 17380558
J Immunol. 2011 Nov 15;187(10):5043-50
pubmed: 21967893
Pharm Biol. 2014 Jan;52(1):124-8
pubmed: 24073600
J Pathol. 2004 Dec;204(5):519-27
pubmed: 15538734
Metabolites. 2012 Apr 16;2(2):303-36
pubmed: 24957513
Inflammation. 1994 Oct;18(5):443-58
pubmed: 7843790
Phytother Res. 2014 Sep;28(9):1406-11
pubmed: 24619567
Mini Rev Med Chem. 2009 Jan;9(1):31-59
pubmed: 19149659
ISRN Dermatol. 2013 Jul 15;2013:812029
pubmed: 23956869
J Invest Dermatol. 2018 Sep;138(9):1990-1998
pubmed: 29559343